These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30259689)

  • 21. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy.
    Chu MP; Lieffers J; Ghosh S; Belch A; Chua NS; Fontaine A; Sangha R; Turner RA; Baracos VE; Sawyer MB
    J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):298-304. PubMed ID: 27897411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low paravertebral muscle mass in patients with bone metastases from lung cancer is associated with poor prognosis.
    Dohzono S; Sasaoka R; Takamatsu K; Hoshino M; Nakamura H
    Support Care Cancer; 2020 Jan; 28(1):389-394. PubMed ID: 31055666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
    Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
    Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer.
    Stene GB; Helbostad JL; Amundsen T; Sørhaug S; Hjelde H; Kaasa S; Grønberg BH
    Acta Oncol; 2015 Mar; 54(3):340-8. PubMed ID: 25225010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy.
    Ma K; Xu W; Wang C; Li B; Su K; Li W
    Cancer Biomark; 2017; 18(3):297-303. PubMed ID: 27983538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
    Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.
    Huang LT; Cao R; Wang YR; Sun L; Zhang XY; Guo YJ; Zhao JZ; Zhang SL; Jing W; Song J; Han CB; Ma J
    BMC Cancer; 2021 Apr; 21(1):426. PubMed ID: 33865364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
    Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
    Pan IW; Mallick R; Dhanda R; Nadler E
    Lung Cancer; 2013 Dec; 82(3):469-76. PubMed ID: 24396885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.
    Mo H; Hao X; Liu Y; Wang L; Hu X; Xu J; Yang S; Xing P; Shi Y; Jia B; Wang Y; Li J; Wang H; Wang Z; Sun Y; Shi Y
    Cancer Med; 2016 Jun; 5(6):1116-24. PubMed ID: 26993156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience.
    Nobili S; Lavacchi D; Perrone G; Vicini G; Tassi R; Landini I; Grosso A; Roviello G; Mazzanti R; Santomaggio C; Mini E
    Oncol Res; 2020 May; 28(3):237-248. PubMed ID: 31806078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy.
    Uemura S; Iwashita T; Ichikawa H; Iwasa Y; Mita N; Shiraki M; Shimizu M
    Br J Nutr; 2021 May; 125(10):1140-1147. PubMed ID: 32883372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
    Spigel DR; Ervin TJ; Ramlau RA; Daniel DB; Goldschmidt JH; Blumenschein GR; Krzakowski MJ; Robinet G; Godbert B; Barlesi F; Govindan R; Patel T; Orlov SV; Wertheim MS; Yu W; Zha J; Yauch RL; Patel PH; Phan SC; Peterson AC
    J Clin Oncol; 2013 Nov; 31(32):4105-14. PubMed ID: 24101053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients.
    Grønberg BH; Valan CD; Halvorsen T; Sjøblom B; Jordhøy MS
    J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1347-1355. PubMed ID: 31385663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K
    Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Li S; Liu Z; Ren Y; Liu J; Lv S; He P; Yang Y; Sun Y; Chang J; Luo D; Cong M
    Front Nutr; 2022; 9():900823. PubMed ID: 35923193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study.
    Shiroyama T; Nagatomo I; Koyama S; Hirata H; Nishida S; Miyake K; Fukushima K; Shirai Y; Mitsui Y; Takata S; Masuhiro K; Yaga M; Iwahori K; Takeda Y; Kida H; Kumanogoh A
    Sci Rep; 2019 Feb; 9(1):2447. PubMed ID: 30792455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of anthropometric measures extracted from whole-body CT using deep learning in patients with non-small-cell lung cancer.
    Blanc-Durand P; Campedel L; Mule S; Jegou S; Luciani A; Pigneur F; Itti E
    Eur Radiol; 2020 Jun; 30(6):3528-3537. PubMed ID: 32055950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.